Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin

References

• Ross DS. Nonpalpable thyroid nodules – managing an epidemic. J. Clin. Endocrinol. Metab.87, 1938–1940 (2002).
   Google Scholar
• Papini E, Guglielmi R, Bianchi A et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features. J. Clin. Endocrinol. Metab.87, 1941–1946 (2002).
   PubMed Web of Science ®Google Scholar
• Mori I, Miyauchi A, Kuma S, Tang W, Kakudo K. Thyroid nodular lesion: analysis of cancer risk based on Kuma Hospital experience. Pathol. Int.53, 579–583 (2003).
   Google Scholar
• Kang HW, No JH, Chung JH et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid14, 29–33 (2004).
   PubMed Web of Science ®Google Scholar
• Frates MC, Benson CB, Doubulet PM et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J. Clin. Endocrinol. Metab.91, 3411–3417 (2006).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Silverberg E, Holleb AI. Cancer statistics 1974. CA Cancer J. Clin.24, 2–21 (1974).
   Google Scholar
• Silverberg E, Holleb AI. Cancer statistics 1975. CA Cancer J. Clin.25, 8–21 (1975).
   Google Scholar
• Seidman H, Silvbery E, Holleb AI. Cancer statistics 1976. CA Cancer J. Clin.26, 14–29 (1976).
   Google Scholar
• Silverberg E. Cancer statistics 1977. CA Cancer J. Clin.27, 26–41 (1977).
   Google Scholar
• Silverberg E. Cancer statistics 1978. CA Cancer J. Clin.28, 17–32 (1978).
   Google Scholar
• Silverberg E. Cancer statistics 1979. CA Cancer J. Clin.29, 6–21 (1979).
   PubMed Web of Science ®Google Scholar
• Silverberg E. Cancer statistics 1980. CA Cancer J. Clin.30, 23–38 (1980).
   Google Scholar
• Silverberg E. Cancer statistics 1981. CA Cancer J. Clin.31, 13–28 (1981).
   Google Scholar
• Silverberg E. Cancer statistics 1982. CA Cancer J. Clin.32, 15–31 (1982).
   PubMed Web of Science ®Google Scholar
• Silverberg E. Cancer statistics 1983. CA Cancer J. Clin.33, 9–25 (1983).
   Google Scholar
• Silverberg E. Cancer statistics 1984. CA Cancer J. Clin.34, 7–23 (1984).
   Google Scholar
• Silverberg E. Cancer statistics 1985. CA Cancer J. Clin.35, 19–35 (1985).
   PubMed Web of Science ®Google Scholar
• Silverberg E. Cancer statistics 1986. CA Cancer J. Clin.36, 9–25 (1986).
   Google Scholar
• Silverberg E, Lubera J. Cancer statistics 1987. CA Cancer J. Clin.37, 2–19 (1987).
   PubMed Web of Science ®Google Scholar
• Silverberg E, Lubera J. Cancer statistics 1988. CA Cancer J. Clin.38, 5–22 (1988).
   PubMed Web of Science ®Google Scholar
• Silverberg E, Lubera J. Cancer statistics 1989. CA Cancer J. Clin.39, 3–20 (1989).
   PubMed Web of Science ®Google Scholar
• Silverberg E, Boring CC, Squires TS. Cancer statistics 1990. CA Cancer J. Clin.40, 9–26 (1990).
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T. Cancer statistics 1991. CA Cancer J. Clin.41, 19–36 (1991).
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T. Cancer statistics 1992. CA Cancer J. Clin.42, 19–38 (1992).
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T. Cancer statistics 1993. CA Cancer J. Clin.43, 7–26 (1993).
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. CA Cancer J. Clin.44, 7–26 (1994).
   PubMed Web of Science ®Google Scholar
• Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J. Clin.45, 8–30 (1995).
   PubMed Web of Science ®Google Scholar
• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J. Clin.46, 5–27 (1996).
   PubMed Web of Science ®Google Scholar
• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J. Clin.47, 5–27 (1997).
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J. Clin.48, 6–29 (1998).
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J. Clin.49, 8–31 (1999).
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J. Clin.50, 7–33 (2000).
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J. Clin.51, 15–36 (2001).
   PubMed Web of Science ®Google Scholar
• Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J. Clin.52, 23–47 (2002).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J. Clin.53, 5–26 (2003).
   PubMed Web of Science ®Google Scholar
• Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin.54, 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J. Clin.56, 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Kosary CL. Cancer of the thyroid. In: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (Eds). National Cancer Institute, SEER Program, Bethesda, MD, USA 217–226 (2007).
   Google Scholar
• McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin. Diagn. Pathol.22, 3–32 (2005).
   PubMed Web of Science ®Google Scholar
• Hatami M, Breining D, Owers RL, Del Priore G, Goldberg GL. Malignant struma ovarii – a case report and review of the literature. Gynecol. Obstet. Invest.65, 104–107 (2008).
   PubMedGoogle Scholar
• Deshpande V, Venkatesh SG. Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Biochim. Biophys. Acta1430, 157–178 (1999).
   PubMedGoogle Scholar
• van de Graaf SAR, Ris-Stalpers C, Pauws E, Mendive FM, Targovnik HM, de Vijlder JJM. Up to date with human thyroglobulin. J. Endocrinol.170, 307–321 (2001).
   PubMed Web of Science ®Google Scholar
• Rasmussen LB, Ovesen L, Bülow I et al. Relations between various measures of iodine intake and thyroid volume, thyroid nodularity, and serum thyroglobulin. Am. J. Clin. Nutr.76, 1069–1076 (2002).
   PubMed Web of Science ®Google Scholar
• van Herle AJ, Uller RP. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J. Clin. Invest.56, 272–277 (1975).
   PubMedGoogle Scholar
• Gerfo PL, Colacchio T, Colacchio D, Feind C. Thyroglobulin in benign and malignant thyroid disease. J. Am. Med. Assoc.241, 923–924 (1979).
   PubMed Web of Science ®Google Scholar
• Hay ID, Thompson GB, Grant CS et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg.26, 870–885 (2002).
   Google Scholar
• Chow S-M, Law SCK, Au S-K et al. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960–2000. Clin. Oncol.15, 329–336 (2003).
   Web of Science ®Google Scholar
• Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery140, 1000–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. J. Am. Med. Assoc.214, 1437–1442 (1970).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine56, 171–196 (1977).
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Clin. Endocrinol. Metab.89, 3668–3676 (2004).
   Google Scholar
• Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J. Surg. Oncol.94, 692–700 (2006).
   PubMed Web of Science ®Google Scholar
• Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J. HK Coll. Radiol.8, 127–135 (2005).
   Google Scholar
• David A, Blotta A, Bondanelli M et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J. Nucl. Med.42, 1470–1475 (2001).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab.87, 1490–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid12, 37–43 (2002).
   PubMed Web of Science ®Google Scholar
• Torlontano M, Crocetti U, Augello G et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J. Clin. Endocrinol. Metab.91, 60–63 (2006).
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated carcinoma of the follicular epithelium. Eur. J. Endocrinol.154, 787–803 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR et al. Management guideline for patients with thyroid nodules and differentiated thyroid cancer. Thyroid16, 109–140 (2006).
   PubMed Web of Science ®Google Scholar
• Pacini F, Agate L, Elisei R et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J. Clin. Endocrinol. Metab.86, 4092–4097 (2001).
   PubMed Web of Science ®Google Scholar
• Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab.88, 1107–1111 (2003).
   PubMed Web of Science ®Google Scholar
• Torlontano M, Attard M, Crocetti U et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J. Clin. Endocrinol. Metab.89, 3402–3407 (2004).
   PubMed Web of Science ®Google Scholar
• Toubeau M, Touzery C, Arveux P et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J. Nucl. Med.45, 988–994 (2004).
   PubMed Web of Science ®Google Scholar
• Pilli T, Brianzoni E, Capoccetti F et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J. Clin. Endocrinol. Metab.92, 3542–3546 (2007).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.88, 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid13, 3–126 (2003).
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen U, Bech K, Date J. Serum thyroglobulin in patients with toxic and non-toxic goitres compared with sex- and age-matched control subjects. Acta Endocrinol. (Copenhagen)91, 264–270 (1979).
   Google Scholar
• Gardner DF, Rothman J, Utiger RD. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves’ disease: effects of T3, iodide, 131I and antithyroid drugs. Clin. Endocrinol.11, 585–594 (1979).
   PubMedGoogle Scholar
• Spencer CA, Fatemi S. Thyroglobulin measurements in thyroid cancer evaluation and surveillance. In: Thyroid Neoplasms. BR Haugen (Ed.). Elsevier, Amsterdam, Holland; Boston, USA 83–105 (2005).
   Google Scholar
• Jensen E, Petersen PH, Blaabjerg O, Hegedus L. Biological variation of thyroid autoantibodies and thyroglobulin. Clin. Chem. Lab. Med.45, 1058–1064 (2007).
   Google Scholar
• Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab.4(4), 223–233 (2008).
   PubMedGoogle Scholar
• Gao Y, Yuan Z, Yu Y, Lu H. Mutual interference between serum thyroglobulin and anti-thyroglobulin antibody in an automated chemiluminescent immunoassay. Clin. Biochem.40, 735–738 (2007).
   Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.83, 1121–1127 (1998).
   PubMed Web of Science ®Google Scholar
• Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab.90, 5566–5575 (2005).
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Evans C, Moss L, Parkes AB, Premawardhana LD, Lazarus JH. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin. Chem.51, 729–734 (2005).
   PubMed Web of Science ®Google Scholar
• Rosário PWS, Maia FFR, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq. Bras. Endocrinol. Metabol.48, 487–492 (2004).
   PubMedGoogle Scholar
• Gorges R, Maniecki M, Jentzen W et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur. J. Endocrinol.153, 49–55 (2005).
   PubMed Web of Science ®Google Scholar
• Chung JK, Park YJ, Kim TY et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol.57, 215–221 (2002).
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Liu YY, Stokkel M et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin. Endocrinol.66, 58–64 (2007).
   PubMed Web of Science ®Google Scholar
• Aras G, Gultekin SS, Kucuk NO, Genc Y. Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer? Nucl. Med. Commun.28, 907–913 (2007).
   PubMed Web of Science ®Google Scholar
• Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin. Chem.42, 661–663 (1996).
   PubMed Web of Science ®Google Scholar
• Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer98, 41–47 (2003).
   PubMed Web of Science ®Google Scholar
• Marquet PY, Daver A, Sapin R et al. Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Clin. Chem.42, 258–262 (1996).
   Google Scholar
• Ratcliffe JG, Ayoub LA, Pearson D. The measurement of serum thyroglobulin in the presence of thyroglobulin antibodies. Clin. Endocrinol.15, 507–518 (1981).
   PubMed Web of Science ®Google Scholar
• Hoofnagle AN, Werner MH. Serum thyroglobulin: a model of immunoassay imperfection. Clin. Lab. Internat.12, 12–14 (2006).
   Google Scholar
• Chinnappa P, Taguba L, Arciaga R et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J. Clin. Endocrinol. Metab.89, 3705–3709 (2004).
   PubMed Web of Science ®Google Scholar
• Chia SY, Milas M, Reddy SK et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab.92, 468–475 (2007).
   PubMed Web of Science ®Google Scholar
• Ringel MD. Molecular detection of thyroid cancer: differentiating “signal” and “noise” in clinical assays. J. Clin. Endocrinol. Metab.89, 29–32 (2004).
   Google Scholar
• Chiovato L, Latrofa F, Braverman LE et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med.139, 346–351 (2003).
   PubMed Web of Science ®Google Scholar
• Preissner CM, O’Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab.88, 3069–3074 (2003).
   PubMed Web of Science ®Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin. Chem.42, 164–173 (1996).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Miccoli P, Ferdeghini M et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid5, 25–28 (1995).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Miccoli P, Fallahi P et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid13, 479–484 (2003).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Miccoli P, Fallahi P et al. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery140, 1035–1041 (2006).
   PubMedGoogle Scholar
• Schlumberger M, Hitzel A, Toubert ME et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J. Clin. Endocrinol. Metab.92, 2487–2495 (2007).
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ceriani L, Garancini S. High-sensitive 2nd generation thyroglobulin immunoradiometric assay. Clinical application in differentiated thyroid cancer management. Q. J. Nucl. Med.46, 319–322 (2002).
   Google Scholar
• Giovanella L, Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin. Chem. Lab. Med.40, 480–484 (2002).
   Google Scholar
• Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid13, 861–865 (2003).
   PubMed Web of Science ®Google Scholar
• Iervasi A, Iervasi G, Bottoni A et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J. Endocrinol.182, 287–294 (2004).
   Google Scholar
• Giovanella L, Ceriani L, Ghelfo A et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin. Chem. Lab. Med.44, 648–652 (2006).
   PubMedGoogle Scholar
• Smallridge RC, Meek SE, Morgan MA et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J. Clin. Endocrinol. Metab.92, 82–87 (2007).
   PubMed Web of Science ®Google Scholar
• Iervasi A, Iervasi G, Ferdeghini M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin. Endocrinol.67, 434–441 (2007).
   PubMedGoogle Scholar
• Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays? Clin. Endocrinol.68, 338–342 (2008).
   Google Scholar
• Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid14, 959–963 (2004).
   PubMed Web of Science ®Google Scholar
• Uruno T, Miyauchi A, Shimizu K et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J. Surg.29, 483–485 (2005).
   PubMed Web of Science ®Google Scholar
• Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J. Clin. Endocrinol. Metab.91, 1364–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Snozek CL, Chambers EP, Reading CC et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J. Clin. Endocrinol. Metab.92, 4278–4281 (2007).
   PubMed Web of Science ®Google Scholar
• Cunha N, Rodrigues F, Curado F et al. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur. J. Endocrinol.157, 101–107 (2007).
   PubMed Web of Science ®Google Scholar
• Orija IB, Hamrahian AH, Reddy SS. Management of nondiagnostic thyroid fine-needle aspiration biopsy: survey of endocrinologists. Endocr. Pract.10, 317–323 (2004).
   Google Scholar
• Florentine BD, Staymates B, Rabadi M, Barstis J, Black A. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer107, 406–416 (2006).
   Google Scholar
• Borel AL, Boizel R, Faure P et al. Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer. Eur. J. Endocrinol.158, 691–698 (2008).
   PubMed Web of Science ®Google Scholar
• Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol.62, 156–162 (2005).
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. J. Am. Med. Assoc.295, 2164–2167 (2006).
   PubMed Web of Science ®Google Scholar
• McDougall IR, Hay ID. ATA Guidelines: do patients with stage I thyroid cancer benefit from (131). Thyroid17, 595–596 (2007).
   Google Scholar
• Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer56, 531–538. (1985).
   PubMed Web of Science ®Google Scholar
• Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer71, 4022–4029 (1993).
   Google Scholar
• Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathol.23, 319–325 (2007).
   Google Scholar
• Bhattacharyya N, Fried MP. Assessment of the morbidity and complications of total thyroidectomy. Arch. Otolaryngol. Head Neck Surg.128, 389–392 (2002).
   PubMedGoogle Scholar
• Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery133, 180–185 (2003).
   PubMed Web of Science ®Google Scholar
• Rosato L, Avenia N, Bernante P et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J. Surg.28, 271–276 (2004).
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Henry LR, Howard RS et al. Prospective trial of voice outcomes after thyroidectomy: evaluation of patient-reported and clinician-determined voice assessments in identifying post thyroidectomy dysphonia. Surgery143, 732–742 (2008).
   PubMed Web of Science ®Google Scholar
• Spear SA, Theler J, Sorensen DM. Complications after the surgical treatment of malignant thyroid disease. Mil. Med.173, 399–402 (2008).
   Google Scholar
• Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med.39, 1551–1554 (1998).
   PubMed Web of Science ®Google Scholar
• Zettinig G, Hanselmayer G, Fueger BJ et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur. J. Nucl. Med. Mol. Imag.29, 1428–1432 (2002).
   PubMed Web of Science ®Google Scholar
• Mandel SJ, Mandel M. Radioactive iodine and the salivary glands. Thyroid13, 265–271 (2003).
   PubMed Web of Science ®Google Scholar
• Hyer S, Konga A, Pratta B, Harmera C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin. Oncol.19, 83–86 (2007).
   PubMed Web of Science ®Google Scholar
• Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther. Onkol.168, 337–343 (1992).
   Google Scholar
• Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J. Nucl. Med.36, 21–27 (1995).
   Google Scholar
• de Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br. J. Cancer75, 734–739 (1997).
   Google Scholar
• Sandeep TC, Strachan MW, Reynolds RM et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab.91, 1819–1825 (2006).
   Google Scholar
• Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab.93, 504–515 (2008).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat. Clin. Pract. Oncol.3, 621–632 (2006).
   Google Scholar
• Gloeckler Ries LA, Eisner MP. Cancer of the female breast. In: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. Gloeckler Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (Eds). National Cancer Institute, SEER Program, Bethesda, MD, USA 101–110 (2007).
   Google Scholar